Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19

J Neurol Sci. 2020 Nov 15:418:117106. doi: 10.1016/j.jns.2020.117106. Epub 2020 Sep 2.

Authors

Samir Abu-Rumeileh¹, Tamara Garibashvili², Wolfgang Ruf², Tanja Fangerau², Jan Kassubek², Katharina Althaus², Markus Otto², Makbule Senel³

Affiliations

¹ Department of Neurology, University of Ulm, Ulm, Germany. Electronic address: samir.abu-rumeileh@uni-ulm.de.
² Department of Neurology, University of Ulm, Ulm, Germany.
³ Department of Neurology, University of Ulm, Ulm, Germany. Electronic address: makbule.senel@uni-ulm.de.

Abstract

•
A clinical worsening in CIDP may occur in concomitance with COVID-19.
•
Cytokine hyperactivation triggered by SARS-CoV-2 infection might be a possible mechanism.
•
The management of these patients is particularly challenging.

Keywords: CIDP; COVID-19; Coronavirus; Neuroimmunology; Neurology; SARS-CoV-2; myasthenia gravis; polyneuropathy.

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections*
Humans
Myasthenia Gravis*
Pandemics*
Pneumonia, Viral*
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating* / complications
SARS-CoV-2